siRNA delivery using nanocarriers - An efficient tool for gene silencing

Current Gene Therapy

Volumn 10, Issue 2, 2010, Pages 139-155

  Khurana, Bharat ^a   Goyal, Amit K ^a   Budhiraja, Abhishek ^a   Arora, Daisy ^a   Vyas, Suresh P ^b  

^a MESCO College of Pharmacy   (India)

^b DR H S GOUR UNIVERSITY   (India)

Author keywords

Gene silencing; Non viral vector; Polymeric systems; siRNA; Viral vector

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; ALGINIC ACID; CARDIOLIPIN; CHITOSAN; LENTIVIRUS VECTOR; LIPOPLEX; LIPOSOME; NANOCARRIER; NANOPARTICLE; RETROVIRUS VECTOR; SMALL INTERFERING RNA; VIRUS VECTOR;

AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HEPATITIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RESPIRATORY TRACT DISEASE; REVIEW; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE SILENCING; GENE THERAPY; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; RNA, SMALL INTERFERING;

EID: 77950929285     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310791111010     Document Type: Review

References (203)

1. Somia N, Verma IM. Gene Therapy: trials and tribulation. Nat Rev Genet 2000; 1: 91-99.
2. Pelletier R, Caron SOP, Puymirat J. RNA based gene therapy for dominantly inherited diseases. Curr Gene Ther 2006; 6: 131-146.
3. Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature 2004; 427: 779-781.
4. Montgomery MK. RNA interference: historical overview and significance, In: Gott JM, Ed., RNA interference, editing, and modification: methods and protocols, New Jersey: Human press 2007; pp. 3-21.
5. Paddison PJ. RNA Interference in mammalian cell systems, In: Paddison PJ, Vogt PK, Eds., RNA interference. Springer-Verlag Berlin Heidelberg, 2008; pp. 1-20.
6. Cejka D, Losert D, Wacheck V. Short interfering RNA (siRNA): tool or therapeutic Clinical. Science 2006; 110: 47-58. (Pubitemid 43059044)
7. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737-747.
8. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
9. Elbashir SM, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001; 20: 6877-6888. (Pubitemid 33134217)
10. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21 and 22 nt RNAs. Genes Dev 2001; 15: 188-200.
11. Chen M, Du Q, Zhang HY, et al. Vector-based siRNA delivery strategies for high-throughput screening of novel target genes. J RNAi Gene Silencing 2005; 1: 5-11.
12. Leung PK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005; 107: 222-239. (Pubitemid 40910042)
13. Raoul C, Barker SD, Aebischer P. Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther 2006; 13: 487-495.
14. Dykxhoorn DM, Novina CD, Sharp PA. Sharp, Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Bio 2003; 4; 457-467.
15. Mil AV, Doevendans PA, Sluijter JPD. The Potential of Modulating Small RNA Activity In Vivo. Mini-Rev Med Chem 2009; 9: 235-248.
16. Castanotto D, Rossi JJ. The promises and pitfalls of RNAinterference- based therapeutics. Nature 2009; 457: 426-433.
17. Reddy LS, Sarojamma V, Ramakrishna V. RNAi in medicine: current and future perspectives. Biotechnol Mol Biol Rev 2006; 1: 103-114.
18. Jana S, Chakraborty C, Nandi S. et al. RNA interference: potential therapeutic targets, Appl Microbiol Biotechnol 2004; 65: 649-657. (Pubitemid 39506545)
19. Watson JD, Crick FHC. A Structure for deoxyribose nucleic acid. Nature 1953; 171: 737-738.
20. Izant J., Weintraub H. Inhibition of thymidine kinase gene expression by antisense RNA: a molecular approach to genetic analysis. Cell 1984; 36: 1007-1015. (Pubitemid 14077960)
21. Russev G. RNA Interference. Biotechnol biotechnol EQ 2007; 283-286.
22. Nellen W, Lichtenstain C. What makes an mRNA anti-sensitive? Trends Biochem Sci 1993; 18: 419-423.
23. Bi F, Liu N, Fan D. Small Interfering RNA: a new tool for gene therapy. Curr Gene Ther 2003; 3: 411-417.
24. Szweykowska-Kulinska Z. RNA interference and its role in the regulation of eukaryotic gene expression. RNA interference 2003; 50: 217-229. (Pubitemid 37034244)
25. Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett 2005; 579: 5822-5829.
26. Ketting RF, Fischer SEJ, Bernstein E, et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 2001; 15: 2654-2659. (Pubitemid 32988876)
27. Nykanen A, Haley B, Zamore PD.ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001; 107: 309-321. (Pubitemid 33049975)
28. Miyoshi K, Tsukumo H, Nagami T, et al. Slicer function of Drosophila Argonautes and its involvement in RISC formation. Genes Dev 2005; 19: 2837-2848.
29. Chiu YL, Rana TM. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 2002; 10: 549-561.
30. Haley B, Zamore PD. Kinetic analysis of the RNAi enzyme complex. Nature Struct Mol Biol 2004; 11: 599-606. (Pubitemid 38823525)
31. Song JJ, Joshua-Tor L. Argonaute and RNA-getting into the groove. Curr Opin Struct Biol 2006; 16: 5-11
32. Tolia NH, Joshua-Tor L. Slicer and the argonautes. Nat Chem Biol 2007; 3: 36-43.
33. Zamore PD, Tuschl T, Sharp PA, et al. RNAi: double- stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33.
34. Preall JB, He Z, Gorra JM. Short interfering RNA strand selection is independent of dsRNA processing polarity during RNAi in Drosophila. Curr Biol 2006; 16: 530-535. (Pubitemid 43343716)
35. Vidugirieṅ J, Goueli S, Suziedelis K. RNA interference: from a research tool to a novel therapeutic agent. Acta Med Lituanica 2007; 14: 165-169.
36. Ngo H, Tschudi C, Gull K, Ullu E. Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc Natl Acad Sci USA 1998; 95: 14687-14692.
37. Kennerdell JR, Carthew RW. Use of dsRNA-mediated genetic interference to demonstrate that frizzeled and frizzeled 2 act in the wingless pathway. Cell 1998; 95: 1017-1026.
38. Lohmann JU, Endl I, Bosch TC. Silencing of developmental genes in Hydra. Dev Biol 1999; 214: 211-214.
39. Wargelius A, Ellingsen S, Fjose A. Double-stranded RNA induces specific developmental defects in zebrafish embryos. Biochem Biophys Res Commun 1999; 263: 156-161. (Pubitemid 29443656)
40. Oelgeschlager M, Larrain J, Geissert D, et al. The evolutionarily conserved BMP-binding protein twisted gastrulation promotes BMP signalling. Nature 2000; 405: 757-763. (Pubitemid 30407840)
41. Wianny F, Zernicka-Goetz M. Specific interference with gene function by double-stranded RNA in early mouse development. Nat Cell Biol 2000; 2: 70-75.
42. Cogni C, Irelan JT, Schumacher M, et al. Transgene silencing of the al-1 gene in vegetative cells of Neurospora is mediated by a cytoplasmic effector and does not depend on DNA-DNA interactions or DNA methylation. EMBO J 1996; 15: 3153-3163.
43. Waterhouse PM, Graham MW, Wang MB. Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA. Proc Natl Acad Sci USA 1998; 95: 13959-13964.
44. De Fougerolles AR. Delivery vehicles for small interfering RNA In Vivo. Hum Gene Ther 2008; 19:125-132.
45. Oliveira S, Hogset A, Storm G et al. Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, In Vitro and In Vivo. Curr Pharm Des 2008; 14: 3686-3697.
46. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006; 11: 67-73.
47. Schiffelers RM, Woodle MC, Scaria P. Pharmaceutical prospects for RNA interference. Pharm Res 2004; 21: 1-7.
48. White PJ. Barriers to successful delivery of short interfering RNA after systemic administration. Clin Exp Pharmacol Physiol 2008; 35: 1371-1376.
49. Zhang S, Zhao B, Jiang H, et al. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 2007; 123: 1-10. (Pubitemid 47444388)
50. Lovett-Racke AE. Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004; 21: 719-731.
51. Filleur S. siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003; 63: 3919-3922.
52. Thakker DR. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 2004; 101:17270-17275.
53. Tolentino MJ. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a non-human primate, laser-induced model of choroidal neovascularization. Retina 2004; 24:132-138. (Pubitemid 38240851)
54. Giladi H. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8: 769-776. (Pubitemid 37527452)
55. Zhang X. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 2004; 279: 10677-10684. (Pubitemid 38372680)
56. Perl M. Silencing of fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am J Pathol 2005; 167: 1545-1559. (Pubitemid 41713309)
57. Dorn G. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004; 32: e49.
58. Klein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003; 125: 9-18.
59. Duxbury MS, Ito H, Zinner MJ, et al. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004; 23: 1539-1548. (Pubitemid 38406516)
60. Lingor P, Koeberle P, Kugler S, et al. Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain 2005; 128: 550-558. (Pubitemid 40380190)
61. Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-55. (Pubitemid 40215837)
62. Li BJ. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nat Med 2005; 11: 944-951.
63. Mohammed A, Dasaradhi PV, Bhatnagar RK, et al. In vivo gene silencing in Plasmodium berghei-A mouse malaria model. Biochem Biophys Res Commun 2003; 309: 506-511.
64. Liu C, Zhang N. Pharmaceutical strategies enhancing cell penetration efficiencies of non-viral gene delivery systems. Curr Gene Ther 2009; 9: 267-290.
65. Lekha DK, Clarke AR. Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Adv Drug Del Rev 2007; 59: 87-100.
66. Collins SA, Guinn BA, Harrison PT, et al. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther 2008; 8: 66-78.
67. Singer O, Verma IM. Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr Gene Ther 2008; 8: 483-488.
68. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406. (Pubitemid 36278858)
69. Janas J, Skowronski J, Van Aelst L. Lentiviral delivery of RNAi in hippocampal neurons. Methods Enzymol 2006; 406: 593-605. (Pubitemid 43207471)
70. Hu W, Huang J, Mahavadi S, et al. Lentiviral siRNA silencing of sphingosine-1-phosphate receptors S1P1 and S1P2 in smooth muscle. Biochem Biophys Res Commun 2006; 343: 1038-1044. (Pubitemid 44313844)
71. Shen C, Buck AK, Liu X. et al. Gene silencing by adenovirus-delivered siRNA. FEBS Lett 2003; 539: 111-114.
72. Chen Y, Chen H, Hoffmann A, et al. Adenovirus-mediated small-interference RNA for in vivo silencing of angiotensinAT1a receptors inmouse brain. Hypertension 2006; 47: 230-237.
73. Huang B, Kochanek S. Adenovirus-mediated silencing of huntingtin expression by shRNA. Hum Gene Ther 2005; 16: 618-626. (Pubitemid 40740929)
74. Cave E, Weinberg MS, Cilliers T, et al. Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retrovirus 2006; 22: 401-410. (Pubitemid 43787764)
75. Kawakami S, Hashida M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007; 22: 142-151.
76. Midoux P, Breuzard G, Gomez JP et al. Polymer-based gene delivery: A current review on the uptake and intracellular trafficking of polyplexes. Curr Gene Ther 2008; 8: 335-352.
77. Philipp A, Meyer M, Wagner E. Extracellular targeting of synthetic therapeutic nucleic acid formulations. Curr Gene Ther 2008; 8: 324-334.
78. Han S, Mahato RI, Sung YK, et al. Development of biomaterials for gene therapy. Mol Ther 2000; 2: 302-317.
79. Tong AW, Jay CM, Senzer N et al. Systemic therapeutic gene delivery for cancer: crafting Paris' Arrow. Curr Gene Ther 2009; 9: 45-60.
80. Gilmore IR, Fox SP, Hollins AJ et al. Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv 2006; 3: 147-155. (Pubitemid 43738986)
81. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7417.
82. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86: 6077-6081.
83. Fattal E, Couvreur P, Dubernet C. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev 2004; 56: 931-946.
84. Montier T, Benvegnu T, Jaffres PA, et al. Progress in cationic lipid-mediated gene transfection: A series of bio-inspired lipids as an example. Curr Gene Ther 2008; 8: 296-312.
85. Gao X, Kim KS, Liu D. Nonviral gene delivery: What we know and what is next. AAPS J 2007; 9: E92-103.
86. De- Fougerolles A, Vornlocher HP, Maraganore J, et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev 2007; 6: 443-453. (Pubitemid 47064567)
87. Dalby B, Cates S, Harris A, et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 2004; 33: 95-103.
88. Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004; 43: 13348-13356. (Pubitemid 39391135)
89. Barteau B, Chevre R, Letrou-Bonneval E, et al. Physicochemical parameters of non-viral vectors that govern transfection efficiency. Curr Gene Ther 2008; 8: 313-323.
90. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009; 61: 721-731.
91. Zuhorn IS, Engberts JBFN, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 2007; 36: 349-362. (Pubitemid 46626209)
92. Xu Y, Szoka FC. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996; 35: 5616-5623. (Pubitemid 26143656)
93. Farhood H, Serbina N, Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta 1995; 1235: 289-295.
94. Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta 1995; 1235: 296-304.
95. Lei G, MacDonald RC. Lipid bilayer vesicle fusion: intermediates captured by high-speed microfluorescence spectroscopy. Biophys J 2003; 85:1585-1599. (Pubitemid 37052244)
96. Akhtara S, Hughesa MD, Khana A, et al. The delivery of antisense therapeutics. Adv Drug Deliv Rev 2000; 44: 3-21.
97. Hughes J, Astriab A, Yoo H, et al. In vitro transport and delivery of antisense oligonucleotides. Methods Enzymol 2000; 313: 342-358.
98. Farhood H, Bottega R, Epand RM, et al. Effect of cationic cholesterol derivatives on gene-transfer and protein-kinase-C activity. Biochim Biophys Acta 1992; 1111: 239-246.
99. Zelphati O, Szoka FC. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 1996; 13: 1367-1372. (Pubitemid 26344983)
100. Ouahabi A, Thiry M, Pector V. The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett 1997; 414: 187-192. (Pubitemid 27389360)
101. Behr JP, Demeneix B, Loeffler JP, et al. Efficient gene transfer into mammalian primary endocrine cells with lipopolyaminecoated DNA. Proc Natl Acad Sci USA 1989; 86 : 6982-6986. (Pubitemid 19240851)
102. Sternberg B, Sorgi FL, Huang L. et al. New structures in complex formation between DNA and cationic liposomes visualized by freezefracture electron microscopy. FEBS Lett 1994; 356: 361-366. (Pubitemid 24377008)
103. Lin AJ, Slack NL, Ahmad A. et al. Three-dimensional imaging of lipid gene-carriers: membrane charge density controls universal transfection behavior in lamellar cationic liposome-DNA complexes. Biophys J 2003; 84: 3307-3316. (Pubitemid 36531778)
104. Khoury M, Louis-Plence P, Escriou V. et al. Apparailly, Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arthritis Rheum 2006; 54: 1867-1877. (Pubitemid 43877936)
105. Foged C, Nielsen HM, Frokjaer S. Liposomes for phospholipase A2 triggered siRNA release: Preparation and in vitro test. Int J Pharm 2007; 331: 160-166.
106. Wu SY, Putral LN, Liang M, et al. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res 2009; 26: 512-522.
107. Yuba E, Kojima C, Sakaguchi N, et al. Gene delivery to dendritic cells mediated by complexes of lipoplexes and pH-sensitive fusogenic polymer-modified liposomes. J Control Release 2008; 130:77-83.
108. Auguste DT, Furman K, Wong A, et al. Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J Control Release 2008; 130: 266-274.
109. Sioud M, Søensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003; 312: 1220-1225. (Pubitemid 37490947)
110. Sorensen DR, Leirdal M, Sioud M, Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327: 761-766. (Pubitemid 36315917)
111. Hassani Z, Lemkine GF, Erbacher P, et al. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J Gene Med 2005; 7: 198-207. (Pubitemid 40348024)
112. Tagami T, Barichello JM, Kikuchi H, et al. The gene-silencing effect of siRNA in cationic lipoplexes is enhanced by incorporating pDNA in the complex. Int J Pharm 2007; 333: 62-69. (Pubitemid 46283268)
113. Ma Z, Li J, He F, et al. Cationic lipids enhance siRNA-mediated interferon response in mice, Biochem. Biophys Res Commun 2005; 330: 755-759. (Pubitemid 40462151)
114. Miyawaki-Shimizu K, Predescu D, Shimizu J, et al. siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am J Physiol Lung Cell Mol Physiol 2006; 290: L405-L413.
115. Landen CN, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005; 65: 6910-6918.
116. Sato A, Takagi M, Shimamoto A, et al. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice, Biomaterials 2007; 28: 1434-1442. (Pubitemid 44959042)
117. Flynn MA, Casey DG. Todryk SM. Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflammation 2004; 1: 1-12.
118. Huckriede A, Jonge JD, Holtrop M et al. Cellular delivery of siRNA mediated by fusion-active virosomes. J. Liposome Res 2007; 17: 39-47. (Pubitemid 46631137)
119. Nakamura Y, Kogure K, Futaki S et al. Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release 2007; 119: 360-367. (Pubitemid 46770881)
120. Hatakeyama H, Ito E, Akita H, et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J Control Release 2009; 139: 127-132.
121. Arnold AS. Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. J Hypertens 2007; 25: 197-205.
122. Palliser D. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006; 439: 89-94. (Pubitemid 43053634)
123. Pal A. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf- 1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 2005; 26: 1087-1091.
124. Yin C, Xi L, Wang X. et al. Silencing heat shock factor 1 by small interfering RNA abrogates heat shock-induced cardioprotection against ischemia-reperfusion injury in mice. J Mol Cell Cardiol 2005; 39: 681-689. (Pubitemid 41331056)
125. Chien PY. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 2005; 12: 321-328.
126. Zimmermann TS. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441:111-114. (Pubitemid 43827961)
127. Pirollo KF. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007; 67: 2938-2943.
128. Nakamura H. RNA interference targeting transforming growth factor- beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vision 2004; 10: 703-711. (Pubitemid 41358224)
129. Li CX, Parker A, Menocal E, et al. Delivery of RNA Interference. Cell Cycle 2006; 5: 2103-9
130. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007; 121: 64-73. (Pubitemid 47126065)
131. Fabre JW, Collins L. Synthetic peptides as non-viral DNA vectors. Curr Gene Ther 2006; 6: 459-480. (Pubitemid 44194391)
132. Schaffert D, Wagner E. Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther 2008; 15: 1131-1138.
133. Kawakami S, Hashida M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007; 22: 142-151.
134. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-7301.
135. Vicennati P, Giuliano A, Ortaggi G et al. Polyethylenimine in medicinal chemistry. Current Medicinal Chemistry 2008; 15: 2826-2839.
136. Fischer D, Bieber T, Li Y, et al. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999; 16: 1273-1279. (Pubitemid 29393618)
137. Werth S, Urban-Klein B, Dai L, et al. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes, J Control Release 2006; 112: 257-270.
138. Patnaik S, Aggarwal A, Nimesh S, et al. PEI-alginate nanocomposites as efficient in vitro gene transfection agents. J Control Release 2006; 114: 398-409.
139. Ge Q, Filip L, Bai A, et al. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004; 101: 8676-8681. (Pubitemid 38745830)
140. Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005; 12: 461-466. (Pubitemid 40394299)
141. Grayson AC, Doody AM, Putnam D, et al. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 2006; 23: 1868-1876. (Pubitemid 44200551)
142. Zintchenko A, Philipp A, Dehshahri A, et al. Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug Chem 2008; 19: 1448-55.
143. Ahn CH, Chae SY, Bae YH, et al. Biodegradable poly (ethylenimine) for plasmid DNA delivery. J Control Release 2002; 80: 273-282.
144. Kim WJ, Chang CW, Lee M, et al. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release 2007; 118: 357-363. (Pubitemid 46441547)
145. Jeong JH, Christensen LV, Yockman JW, et al. Reducible poly (amido ethylenimine) directed to enhance RNA interference. Biomaterials 2007; 28: 1912-1917.
146. Breunig M, Hozsa C, Lungwitz CU, et al. Mechanistic investigation of poly (ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo. J Control Release 2008; 130: 57-63.
147. Liu C, Zhao G, Liu et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release 2009; 140: 277-283.
148. Tong H, Shi Q, Fernandes JC, et al. Progress and prospects of chitosan and its derivatives as non viral gene vectors in gene therapy. Curr Gene Ther 2009; 9: 495-502.
149. Pille JY, Li H, Blot E, et al. Intravenous delivery of anti-rhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 2006; 17: 1019-1026. (Pubitemid 46076743)
150. Liua X, Howarda KA, Dong M, et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing Biomaterials 2007; 28: 1280-8
151. Katas H, Alpar HO. Development and characterization of chitosan nanoparticles for siRNA delivery. J Control Release 2006; 115: 216-225. (Pubitemid 44559708)
152. Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neugene via RNA interference. Biomaterials 2007; 28: 1565-1571. (Pubitemid 46039833)
153. Jere D, Jiang HL, Xu CX, et al. Efficient chitosan-graft-polyethylenimine for Akt1 siRNA delivery to non small cell lung carcinoma cell line. Int J Pharm 2009; 378: 194-200.
154. Zhang W, Yang H, Kong X, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005; 11: 56-62. (Pubitemid 40215838)
155. Howard K, Kjems J. RNA interference in vitro and in vivo using a chitosan/siRNA Nanoparticle system. Mol Ther 2006; 14: 476-484.
156. Bartlett DW, Davis ME. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 2008; 99: 975-985.
157. Hu-Lieskovan S, Heidel JD, Bartlett DW. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-8992. (Pubitemid 41377390)
158. Heidel JD, Yu Z, Liu JY, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 2007; 104: 5715-5721. (Pubitemid 47175600)
159. Hu-Lieskovan S, Heidel JD, Bartlett DW et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-8992. (Pubitemid 41377390)
160. Bartlett,DW, Su H, Hildebrandt IJ,et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007; 104: 15549-15554. (Pubitemid 47502954)
161. Heidel JD, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 2007; 104: 5715-5721.
162. Aigner A, Cellular Delivery in vivo of siRNA-based therapeutics. Curr Pharm Des 2008; 14: 3603-3619.
163. Ochiya T, Takahama Y, Nagahara S, et al. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 1999; 5: 707-710.
164. Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004; 32: e109.
165. Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 2006; 107: 864-873. (Pubitemid 44232679)
166. Takei Y, Kadomatsu K, Yuzawa Y, et al. Small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-3370. (Pubitemid 38657905)
167. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bonemetastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-12182. (Pubitemid 41291148)
168. Matoba T, Orba Y, Suzuki T, et al. An siRNA against JC virus (JCV) agnoprotein inhibits JCV infection in JCV-producing cells inoculated in nude mice. Neuropathology 2008; 28: 286-294. (Pubitemid 351623770)
169. Patnaik S, Aggarwal A, Nimesh S, et al. PEI-alginate nanocomposites as efficient in vitro gene transfection agents. J Control Release 2006; 114(3):398-409. (Pubitemid 44310821)
170. Patnaik S, Arif M, Pathak A et al. PEI-alginate nanocomposites: efficient non-viral vectors for nucleic acids. Int J Pharm 2010; 385(1-2):194-202.
171. Lee DW, Yun KS, Ban HS, et al. Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release 2009; 139(2):146-152.
172. Krebs MD, Jeon O, Alsberg E. Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels, J Am Chem Soc 2009; 131 (26): 9204-9206.
173. Khan A. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004; 12: 393-404. (Pubitemid 39302465)
174. Nguyen J, Steele TWJ, Merkel O et al. Fast degrading polyesters as siRNA nanocarriers for pulmonary gene therapy. J Control Release 2008; 132: 243-251.
175. Patil Y, Panyamb J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 2009; 367: 195-203.
176. Kim Y, Tewari M, Pajerowski JD et al. Polymersome delivery of siRNA and antisense oligonucleotides.J Control Release 2009; 134: 132-140.
177. Chowdhury EH, Akaike T. Bio-functional inorganic materials: An attractive branch of gene-based nano-medicine delivery for 21st Century. Curr Gene Ther 2005; 5: 669-676. (Pubitemid 43009510)
178. Liang XJ, Chen C, Zhao Y et al. Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr Drug Metab 2008; 9: 697-709.
179. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 2005; 9(6): 674-679. (Pubitemid 41612196)
180. Podesta JE, Al-Jamal KT, Herrero MA, et al. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009; 5(10):1176-1185.
181. Krajcik R, Jung A, Hirsch A, et al. Functionalization of carbon nanotubes enables non-covalent binding and intracellular delivery of small interfering RNA for efficient knock-down of genes. Biochem Biophys Res Commun 2008; 369(2): 595-602.
182. Zhang Z, Yang X, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006; 12(16): 4933-4939. (Pubitemid 44338581)
183. Yang R, Yang X, Zhang Z, et al. Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther 2006; 13(24):1714-1723. (Pubitemid 44849036)
184. Giljohann DA, Seferos DS, Prigodich AE, et al. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc 2009; 131(6): 2072-2083.
185. Elbakry A, Zaky A, Liebl R, et al. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett 2009; 9(5): 2059-2064.
186. Lee JS, Green JJ, Love KT, et al. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett 2009; 9(6): 2402-2406.
187. Song WJ, Du JZ, Sun TM, et al. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small 2010; 6(2): 239-246.
188. DeLong RK, Akhtar U, Sallee M, et al. Characterization and performance of nucleic acid nanoparticles combined with protamine and gold. Biomaterials 2009; 30(32): 6451-6459.
189. Bonoiu AC, Mahajan SD, Ding H, et al. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci USA 2009; 106(14): 5546-5550.
190. Ladewig K, Niebert M, Xu ZP et al. Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles. Biomaterials 2010; 31(7): 1821-1829.
191. Kovtun A, Heumann R, Epple M. Calcium phosphate nanoparticles for the transfection of cells. Biomed Mater Eng 2009; 19(2-3): 241-247.
192. Lia J, Chena Y-C, Tsenga Y-C, et al. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 2010; 142(3): 416-421.
193. Kakizawa Y, Furukawa S, Ishii A, et al. Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J Control Release 2006; 111(3): 368-370.
194. Lee JH, Lee K, Moon SH, et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl 2009; 48(23): 4174-4179.
195. Medarova Z, Kumar M, Ng SW, et al. Multifunctional magnetic nanocarriers for image-tagged SiRNA delivery to intact pancreatic islets. Transplantation 2008; 86(9): 1170-1177.
196. Xia T, Kovochich M, Liong M, et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 2009; 3(10): 3273-3276.
197. Liu B. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA. Brief Funct Genomics Proteomics 2007; 6: 112-119. (Pubitemid 351721074)
198. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. RNA Appl Microbiol Biotechnol 2007; 76: 9-21. (Pubitemid 47194678)
199. Sanguino A, Berestein GL, Sood AK. Strategies for In Vivo siRNA delivery in cancer. Mini-Rev Med Chem 2008; 8: 248-255.
200. Fountaine TM, Wood MJA, Martins RW. Delivering RNA interference to the mammalian brain. Curr Gene Ther 2005; 5: 399-410. (Pubitemid 41052431)
201. Lim F, Diaz-Nido J. Gene therapy approaches to Ataxias. Curr Gene Ther 2009; 9: 1-8.
202. Lee CC, Chiang BL. RNA interference: new therapeutics in allergic diseases. Curr Gene Ther 2008; 8: 236-246.
203. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nature 2009; 8: 129-138.